Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis

ICER determined that Vivus’ Qsymia, the brand name for the appetite suppressant phentermine combined with the anticonvulsant topiramate, was more cost effective for weight loss than other competitors such as Novo Nordisk’s Saxenda and Wegovy.